Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

81.01 -0.82 (-1.00%)
Official Closing Price Updated: 4:15 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
From DexCom, Inc.
Via Business Wire
Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Expert Outlook: DexCom Through The Eyes Of 8 Analysts
Via Benzinga
Lifshitz Law PLLC Announces Investigations of Nano Nuclear Energy, Inc. (NASDAQ: NNE), Extreme Networks, Inc. (NASDAQ: EXTR), DexCom, Inc. (NASDAQ: DXCM), and Methode Electronics, Inc. (NYSE: MEI)
Via ACCESS Newswire
Forecasting The Future: 7 Analyst Projections For DexCom
Via Benzinga
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
1 Cash-Producing Stock on Our Buy List and 2 to Be Wary Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Exposures Product Safety
DEXCOM INC (NASDAQ:DXCM) – A Strong Growth Stock with a Bullish Technical Setup
DEXCOM INC (NASDAQ:DXCM) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
DEXCOM INC (NASDAQ:DXCM) - A Technical Breakout Candidate Worth Watching
DEXCOM INC (NASDAQ:DXCM) shows strong technicals and a high-quality setup, making it a potential breakout candidate. The stock's consolidation and bullish signals suggest a possible upward move. 
Via Chartmill
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
2 Profitable Stocks on Our Watchlist and 1 to Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Supply Chain
Exposures Product Safety Supply Chain
Wednesday's session: top gainers and losers in the S&P500 index
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Wednesday.
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Via The Motley Fool
Topics Government
Exposures Political
2 Momentum Stocks with Impressive Fundamentals and 1 to Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Exposures Product Safety
3 Big Reasons to Love DexCom (DXCM)
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Government Stocks
Exposures Political Product Safety US Equities
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Topics Economy
Exposures Supply Chain
DXC Tech Stock Slides On Sour Guidance, But Retail's Happy As Q4 Results Top Estimates
The company's bookings grew more than 20% for the second straight quarter, and the book-to-bill ratio exceeded one. 
Via Stocktwits
Topics Earnings
Exposures Financial
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
From DexCom, Inc.
Via Business Wire
1 Healthcare Stock with Exciting Potential and 2 to Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 Product Safety US Equities
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market. 
Via MarketBeat
Topics Earnings
Exposures Financial Product Safety
What's Driving the Market Sentiment Around DexCom?
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally. 
Via Benzinga
Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024. 
Via Benzinga
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Via Benzinga
2 Growth Stocks to Buy and Hold for a Decade
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
DexCom (NASDAQ:DXCM) Exceeds Q1 Expectations
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.